V Square Quantitative Management LLC Acquires 3,320 Shares of Johnson & Johnson (NYSE:JNJ)

V Square Quantitative Management LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 7.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,541 shares of the company’s stock after purchasing an additional 3,320 shares during the quarter. Johnson & Johnson accounts for 1.1% of V Square Quantitative Management LLC’s investment portfolio, making the stock its 11th largest position. V Square Quantitative Management LLC’s holdings in Johnson & Johnson were worth $7,380,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of JNJ. CHB Investment Group LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth $594,000. Ellenbecker Investment Group grew its holdings in Johnson & Johnson by 1.6% during the 3rd quarter. Ellenbecker Investment Group now owns 4,531 shares of the company’s stock valued at $734,000 after buying an additional 70 shares in the last quarter. Madrona Financial Services LLC grew its holdings in Johnson & Johnson by 4.4% during the 3rd quarter. Madrona Financial Services LLC now owns 2,033 shares of the company’s stock valued at $329,000 after buying an additional 85 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in Johnson & Johnson by 3.6% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 500,971 shares of the company’s stock valued at $81,187,000 after buying an additional 17,197 shares in the last quarter. Finally, TruWealth Advisors LLC grew its holdings in Johnson & Johnson by 2.4% during the 3rd quarter. TruWealth Advisors LLC now owns 5,491 shares of the company’s stock valued at $890,000 after buying an additional 129 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.2 %

Johnson & Johnson stock traded down $0.26 during trading hours on Friday, reaching $164.21. The stock had a trading volume of 940,633 shares, compared to its average volume of 7,004,460. The stock has a market cap of $395.20 billion, a PE ratio of 10.25, a PEG ratio of 2.65 and a beta of 0.52. The company has a fifty day simple moving average of $162.89 and a 200-day simple moving average of $154.66. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 EPS. Analysts forecast that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. TD Cowen reduced their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. The Goldman Sachs Group lowered their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.